| **Supplemental Table. Staging method (clinical or pathologic) among recipients of neoadjuvant chemotherapy, by SEER stage** | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **All (N=8996)** | | **American Joint Committee on Cancer Stage** | | | | | |
| **I (N=673)** | | **II (N=4378)** | | **III (N=3945)** | |
| **N** | **Column %** | **N** | **Column %** | **N** | **Column %** | **N** | **Column %** |
| **T stage** | 713 | 7.9% | 44 | 6.5% | 346 | 7.9% | 323 | 8.2% |
| Clinical |
| Pathologic | 1307 | 14.5% | 157 | 23.3% | 653 | 14.9% | 497 | 12.6% |
| Clinical, after neoadjuvant chemotherapy (NAC) | 5033 | 55.9% | 264 | 39.2% | 2561 | 58.5% | 2208 | 56.0% |
| yp prefix: T stage higher on post-NAC pathologic than clinical | 1943 | 21.6% | 208 | 30.9% | 818 | 18.7% | 917 | 23.2% |
| **N stage** | 697 | 7.7% | 60 | 8.9% | 376 | 8.6% | 261 | 6.6% |
| Clinical |
| Pathologic | 1533 | 17.0% | 173 | 25.7% | 779 | 17.8% | 581 | 14.7% |
| Clinical, after neoadjuvant chemotherapy (NAC) | 2290 | 25.5% | 105 | 15.6% | 1175 | 26.8% | 1010 | 25.6% |
| yp prefix: N stage higher on post-NAC pathologic than clinical | 4476 | 49.8% | 335 | 49.8% | 2048 | 46.8% | 2093 | 53.1% |